346 related articles for article (PubMed ID: 29178913)
1. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study.
Yang H; Peng Q; Yin L; Li S; Shi J; Zhang Y; Lu X; Shu X; Zhang S; Wang G
Arthritis Res Ther; 2017 Nov; 19(1):259. PubMed ID: 29178913
[TBL] [Abstract][Full Text] [Related]
2. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
[TBL] [Abstract][Full Text] [Related]
3. Cancer associated autoantibodies in idiopathic inflammatory myopathies: A retrospective cohort from a single center in China.
Zhao Y; Su H; Yin X; Hou H; Wang Y; Xu Y; Li X; Zhang N; Sun W; Wei W
Med Clin (Barc); 2023 Jan; 160(1):10-16. PubMed ID: 35842306
[TBL] [Abstract][Full Text] [Related]
4. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China.
Wen L; Chen X; Cheng Q; Nie L; Xu J; Yan T; Zhang X; Yang H; Sun W; Liu L; Xue J; Du Y
Clin Rheumatol; 2022 Nov; 41(11):3419-3427. PubMed ID: 35859245
[TBL] [Abstract][Full Text] [Related]
5. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies.
Wong VT; So H; Lam TT; Yip RM
Acta Neurol Scand; 2021 Feb; 143(2):131-139. PubMed ID: 32762037
[TBL] [Abstract][Full Text] [Related]
6. Anti-TIF1-γ antibody and cancer-associated myositis: A clinicohistopathologic study.
Hida A; Yamashita T; Hosono Y; Inoue M; Kaida K; Kadoya M; Miwa Y; Yajima N; Maezawa R; Arai S; Kurasawa K; Ito K; Shimada H; Iwanami T; Sonoo M; Hatanaka Y; Murayama S; Uchibori A; Chiba A; Aizawa H; Momoo T; Nakae Y; Sakurai Y; Shiio Y; Hashida H; Yoshizawa T; Sakiyama Y; Oda A; Inoue K; Takeuchi S; Iwata NK; Date H; Masuda N; Mikata T; Motoyoshi Y; Uesaka Y; Maeda MH; Nakashima R; Tsuji S; Kwak S; Mimori T; Shimizu J
Neurology; 2016 Jul; 87(3):299-308. PubMed ID: 27343066
[TBL] [Abstract][Full Text] [Related]
7. Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies.
Ghirardello A; Gatto M; Franco C; Zanatta E; Padoan R; Ienna L; Gallo N; Zen M; Lundberg IE; Mahler M; Doria A; Iaccarino L
Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835823
[TBL] [Abstract][Full Text] [Related]
8. [Myositis-specific autoantibodies].
Fujimoto M
Brain Nerve; 2013 Apr; 65(4):449-60. PubMed ID: 23568993
[TBL] [Abstract][Full Text] [Related]
9. Myositis Autoantibody Profiles and Clinical Significance in Patients with Inflammatory Myopathies in Southwest China.
Zhu H; Zhou W; Zheng L; Jiang Y; Lao Y; Li S; Jin M; Wang J; Li X
Clin Lab; 2024 May; 70(5):. PubMed ID: 38747930
[TBL] [Abstract][Full Text] [Related]
10. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients.
Betteridge Z; Tansley S; Shaddick G; Chinoy H; Cooper RG; New RP; Lilleker JB; Vencovsky J; Chazarain L; Danko K; Nagy-Vincze M; Bodoki L; Dastmalchi M; Ekholm L; Lundberg IE; McHugh N;
J Autoimmun; 2019 Jul; 101():48-55. PubMed ID: 30992170
[TBL] [Abstract][Full Text] [Related]
11. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.
Satoh M; Tanaka S; Ceribelli A; Calise SJ; Chan EK
Clin Rev Allergy Immunol; 2017 Feb; 52(1):1-19. PubMed ID: 26424665
[TBL] [Abstract][Full Text] [Related]
12. Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review.
Tiniakou E; Mammen AL
Clin Rev Allergy Immunol; 2017 Feb; 52(1):20-33. PubMed ID: 26429706
[TBL] [Abstract][Full Text] [Related]
13. Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash.
Ichimura Y; Konishi R; Shobo M; Inoue S; Okune M; Maeda A; Tanaka R; Kubota N; Matsumoto I; Ishii A; Tamaoka A; Shimbo A; Mori M; Morio T; Kishi T; Miyamae T; Tanboon J; Inoue M; Nishino I; Fujimoto M; Nomura T; Okiyama N
Rheumatology (Oxford); 2022 Mar; 61(3):1222-1227. PubMed ID: 34152410
[TBL] [Abstract][Full Text] [Related]
14. Narrative review of autoantibodies in idiopathic inflammatory myopathies.
Liu Y; Zheng Y; Hao H; Yuan Y
Ann Transl Med; 2023 Apr; 11(7):291. PubMed ID: 37090051
[TBL] [Abstract][Full Text] [Related]
15. Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies.
Zampeli E; Venetsanopoulou A; Argyropoulou OD; Mavragani CP; Tektonidou MG; Vlachoyiannopoulos PG; Tzioufas AG; Skopouli FN; Moutsopoulos HM
Clin Rheumatol; 2019 Jan; 38(1):125-132. PubMed ID: 30145635
[TBL] [Abstract][Full Text] [Related]
16. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies.
Hengstman GJ; Brouwer R; Egberts WT; Seelig HP; Jongen PJ; van Venrooij WJ; van Engelen BG
J Neurol; 2002 Jan; 249(1):69-75. PubMed ID: 11954871
[TBL] [Abstract][Full Text] [Related]
17. Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology.
Gómez GN; Pérez N; Braillard Poccard A; Gómez RA; Costi AC; García MA; Viola M; Benitez A; Aciar MM; Crespo Espíndola M; Yucra D; Cosatti MA; Pisoni C; Capelusnik D; Lojo MN; Barrios BI; Rivero M; Kisluk B; Granel A
Clin Rheumatol; 2021 Nov; 40(11):4473-4483. PubMed ID: 34159491
[TBL] [Abstract][Full Text] [Related]
18. Long-term risks of malignancy in myositis-specific antibody-positive idiopathic inflammatory myopathy.
Izuka S; Komai T; Shoda H; Fujio K
Rheumatol Int; 2023 Feb; 43(2):335-343. PubMed ID: 36175662
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital.
Suga T; Oiwa H; Ishida M; Iwamoto Y
Clin Rheumatol; 2022 Sep; 41(9):2803-2808. PubMed ID: 35399148
[TBL] [Abstract][Full Text] [Related]
20. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
